Tue, April 17, 2018
Mon, April 16, 2018
Fri, April 13, 2018
Thu, April 12, 2018

David Nierengarten Maintained (BPMC) at Buy with Increased Target to $106 on, Apr 16th, 2018

David Nierengarten of Wedbush, Maintained "Blueprint Medicines Corporation" (BPMC) at Buy with Increased Target from $98 to $106 on, Apr 16th, 2018.

David, nor any peers, have made any analyst calls on BPMC in the last 4 months.

Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30


Similar Stocks and Investing Publications